2019 Academy advocacy priorities

2019-advocacy-issue-booklet-cover.png
Download a PDF version of the 2019 Advocacy Guide

The advocacy arm of the Academy, the American Academy of Dermatology Association (AADA) provides a voice to dermatologists, ensuring that public policies address the ever-changing needs of practices and patient care. The AADA provides members with valuable resources and tools to adapt to the shifting health care landscape while contributing to policies that protect the quality of, and access to dermatologic care.

Advocacy priorities for the coming year include:

access-to-compounding-icon.png

Access to Compounded Medications

Guarding against restrictions on board-certified dermatologists’ ability to prepare, administer, and prescribe compounded medications, which is integral to their provision of value-based patient care. Advocating with the Food and Drug Administration (FDA) and the United States Pharmacopoeia (USP) Convention to ensure any guidance or standards, respectively, do not place unreasonable and burdensome restrictions on the practice of medicine and physician-patient relationship. Also includes fighting, as needed, state pharmacy board regulation of physicians
preparing compounded medications in the clinical setting.

access-to-specialty-care-icon.png

Access to Specialty Care through Private and Public Payers

Ensuring adequate and accurate information is available about provider directories for both
private and public payers; advocating for appropriate reimbursement for services provided;
ensuring that policies within the Medicare program and resulting from implementation of the
VA Mission Act, which gives veterans more options to seek care among community providers,
facilitate beneficiary access to the full range of specialists including Mohs surgeons, as needed.

health-care-market-consolidation-icon.png

Health Care Market Consolidation/Preserving Private Practice

With the current trend toward mergers among health plans, pharmacy benefit managers, etc.,
and the purchase of practices by private equity firms, health systems and other corporate entities, working to preserve the ability of physicians to own/operate their own practices and maintain competitiveness.

medicare-payment-physician-policy-icon.png

Medicare Physician Payment Policy

Advocating for fair reimbursement under the current fee-for-service program; working across
dermatology and within the House of Medicine to preserve the 10- and 90-day global period
payments for medical procedures, and in recognition of the challenges implicit with that effort,
also working on alternative strategies. Remaining vigilant as the Administration has started taking
up some of the limiting strategies of private payers such as prior authorization and reducing
payments when E/M services are reported with procedures.

pharmaceutical-access-icon.png

Pharmaceutical Access and Affordability

Working in collaboration with all stakeholders to minimizing and/or eliminate barriers that
patients face in accessing needed medications, including modifications to step therapy and
prior authorization policies as well as efforts to address rising drug prices and drug shortages.
Also includes supporting efforts to improve price transparency and to advocate for policies that
will encourage competition to lower the cost of medications and improve access to treatment
for patients.

scope-of-practice-icon.png

Scope-of-Practice

Working with all stakeholders to appropriately define the practice of medicine, to ensure a
physician-led, team-based approach to care through the adoption or modification of regulations
to ensure that, as the workforce expands to include greater use of non-physician clinicians,
structures are in place to ensure a focus on the highest level, appropriate care and to ensure
patient safety.

skin-cancer-prevention-icon.png

Skin Cancer Prevention, Access to Sunscreen and Indoor Tanning

Advocating at the federal and state levels to educate policymakers about skin cancer prevention
and detection, and to promote increased regulation of indoor tanning. Working to bridge the
interests of sunscreen manufacturers and federal regulators to ensure fair consideration of new
sunscreen ingredients based on scientific evidence and demonstration of patient/consumer
safety.


Related resources